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We describe an unusual complication of a common disease: stroke presenting in a man recently diagnosed with polymyalgia
rheumatica. Initial inﬂammatory markers were misleading. We discuss pitfalls in diagnosis, and approach to management.
1. Case History
A 63-year-old businessman presented to the emergency
department (ED) with transient left arm weakness, expres-
sive dysphasia, left facial droop, and muscle aches. He
had attended his general practitioner (GP) one month
previouslywithachesandpains:hisGPdiagnosedpolymyal-
gia rheumatica (PMR) and commenced steroid treatment
with signiﬁcant improvement. Before starting steroids, ery-
throcyte sedimentation rate (ESR) was mildly elevated at
22mm/hr; C-reactive protein (CRP) had been modestly
elevated (46mg/L). The patient had stopped steroids two
days prior to admission, with relapse of symptoms.
His medical history was signiﬁcant for ocular migraines,
angina, an upper limb deep venous thrombosis 25 years ago,
and a pulmonary emoblism post-angiogram 9 months ago.
On examination, reduced power was noted in his left
hand with normal speech, no visual ﬁeld abnormalities, and
no facial droop.
Investigations included a normal ESR and CRP. Com-
puted tomography of brain was normal, but magnetic
resonance imaging (MRI) of brain and C-spine (Figure 1)
showed a subacute right posterior parietal infarct with C3-
C4 posterior disc bulge. His left upper limb weakness was
not attributed to cervical myelopathy. Ultrasound of carotids
showed no signiﬁcant stenosis. Antinuclear antibody assay
was negative, as were antineutrophil cytoplasmic antibody
andrheumatoidfactor.Athrombophiliascreenwasnegative.
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giant cell arteritis with concomitant stroke, and he was
treated with high-dose aspirin and oral steroids. A temporal
artery biopsy was scheduled. This was delayed secondary to
worsening of left arm weakness, new left upper quadran-
tanopia,andleftsidedneglect.ArepeatMRIbrain(Figure 2)
showed extension of the right middle cerebral infarct. CRP
was raised at 41mg/L with a normal ESR (6mm/hr). His
steroid treatment was changed to high-dose intravenous
methylprednisolone 1g daily for three days; he subsequently
continued on high-dose oral steroids (prednisolone 60mg
daily).
A temporal artery biopsy performed two weeks post-
admission disclosed a small and ﬁbrotic vessel. Histological
examination conﬁrmed giant cell arteritis.
The patient was discharged with mild weakness in his
left upper limb and minimal functional limitations. He
continued on low-dose aspirin and oral steroids.
2. Discussion
PMR and giant cell arteritis (GCA) are closely related
vasculitic conditions. GCA involves large-sized and medium
sized arteries, most commonly the temporal arteries. PMR
is characterised by aching and morning stiﬀness in the
shoulder, pelvic girdles, and neck. The two disorders can
occur separately or together and it is postulated that they
are diﬀerent manifestations of the same disease process [1].
About 50 percent of patients with GCA also have PMR and
about 10 percent of those with PMR also have GCA [2].
Diagnosis is based on clinical symptoms, raised acute
phase makers, response to glucocorticoids and exclusion
of other disease. Diﬀerent clinical criteria exist to help
diagnosis: the majority (89 percent) include an elevated ESR2 Case Reports in Medicine
Figure 1: Subacute right posterior parietal infarct.
Figure 2:Newsignalabnormalityinthelateraloccipitallobeonthe
right side indicating mild interval progression of the stroke.
[3]. The gold standard for diagnosis remains temporal artery
biopsy.
Unusual presentations of GCA include cough, pyrexia
of unknown origin, and lower limb claudication [4].
Neurological manifestations such as mononeuropathy or
peripheralneuropathycanoccurinapproximately30percent
of patients [5].
Stroke is less common (3-4 percent) [6]. Where stroke
occurs, it may follow a ﬂuctuant course corresponding to the
severityofvasculitis[7]:thismayhavebeenthecasewiththis
patient. In this instance, diagnosis was complicated further
by the patient’s normal ESR and CRP. Low levels of ESR
(<40)havebeenreportedinupto5.4%ofpatientswithGCA
[8]; this patient’s disease seemed unusually aggressive given
the low levels of antiinﬂammatory markers. Anticardiolipin
antibodies have been associated with GCA and with more
severe disease [9], however, this patient’s thrombophilia
screen was negative.
Patients with GCA-associated stroke tend to recover
gradually with prompt administration of corticosteroids [7].
A combination of antiplatelet and corticosteroids may be
advisable for preventing stroke occurrence [10].
3. Conclusion
Stroke is an uncommon but serious complication of GCA.
NormallevelsofESRandCRPdonotprecludethediagnosis.
Temporal artery biopsy should be considered for patients
with stroke and symptoms suggestive of PMR.
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